FINANCIAL STATEMENTS Notes to the Consolidated Financial Statements Continued 36.
Net cash from operating activities 38.
Share-based payments 2015 2014 Equity-settled share option scheme $m $m During the year ended 31 December 2015, the Company had one stock option compensation scheme settled by equity instruments, with Profit before tax 318 362 four separate grant dates.
The options over these instruments are settled in equity once exercised.
Adjustments for: Depreciation, amortisation, and impairment of: Details of the grants under the scheme are shown below: Property, plant and equipment 51 49 The Intangible assets 22 23 estimated fair Expected Investment in associate 7 value of each The share average Gain Loss on disposal of property, plant and equipment 11 1 Number share option price at Exercise Expected Expected contractual Risk free granted granted grant date price volatility dividend yield life interest rate Gain on disposal of intangible assets 1 Date of grants $ $ $ Movement on provisions 3 5 4-Nov-2008 85,000 1.14 5.45 5.45 34.90% 1.21% 4.0 years 4.11% Cost of equity-settled employee share scheme 15 8 29-Apr-2008 1,041,500 2.61 9.19 9.19 31.50% 0.08% 3.8 years 4.54% Finance income 3 4 13-Oct-2005 1,600,000 0.74 4.50 4.50 26.20% 6.67% 7.5 years 4.54% Interest and bank charges 57 38 12-Oct-2004 9,520,000 0.35 0.91 0.91 44.80% 3.85% 7.5 years 4.22% Results from associates 2 6 Cash flow before working capital 461 487 All of the general employees share option plans have a ten-year contractual life and vesting conditions of 20% per year for five years Change in trade and other receivables 78 16 beginning on the first anniversary of the grant date.
Change in other current assets 1 The estimated fair value of each share option granted in the general employee share option plans was calculated by applying a binomial Change in inventories 4 2 option pricing model.
Change in trade and other payables 28 24 It was assumed that each option tranche will be exercised immediately after the vesting date.
Change in other current liabilities 3 7 Cash generated by operations 417 504 Further details of the general employee share option plan are as follows: Income tax paid 51 79 2015 2014 Net cash generated from operating activities 366 425 Weighted Weighted Number of average average share exercise price Number of exercise price 37.
Contingent liabilities options in $ share options in $ A contingent liability existed at the balance sheet date in respect of external guarantees and letters of credit totalling $50 million Outstanding at 1 January 143,500 7.60 228,600 7.33 2014: $45 million.
Exercised during the year 79,700 7.59 61,100 6.67 Expired during the year 51,300 7.10 24,000 0.91 The integrated nature of the Groups worldwide operations, involving significant investment in research and strategic manufacturing Outstanding at 31 December 12,500 9.18 143,500 7.60 at a limited number of locations, with consequential cross-border supply routes into numerous end-markets, gives rise to complexity Exercisable at 31 December 12,500 9.18 143,500 7.60 and delay in negotiations with revenue authorities as to the profits on which individual Group companies are liable to tax.
Disagreements with, and between, revenue authorities as to intra-Group transactions, in particular the price at which goods and services The weighted average share price at the date of exercise for share options exercised during the year was $7.59.
The options outstanding should be transferred between Group companies in different tax jurisdictions, have the potential to produce conflicting claims from at 31 December 2015 had a weighted average remaining contractual life of less than three years.
revenue authorities as to the profits to be taxed in individual territories.
Expected volatility was determined by calculating the historical volatility of the Groups share price over the previous three to four years.
The promotion, marketing and sale of pharmaceutical products and medical devices is highly regulated and the operations of market Long-term incentive plan participants, such as Hikma, are closely supervised by regulatory authorities and law enforcement agencies, including the FDA and the The 2007 Long-Term Incentive Plan LTIP was approved by shareholders at the 2007 Annual General Meeting and the last grant was US Department of Justice.
As a result, the Group is subject to certain investigations by governmental agencies, as well as other various made under the LTIP during the year ended 31 December 2014.
The LTIP is settled by equity instruments, with fifteen separate grant dates.
legal proceedings considered typical to its business relating to employment, product liability and commercial disputes.
Under the LTIP, conditional awards and $nil cost options were granted which vest after three years subject to a total shareholder return TSR, revenue growth, earnings per share and return on invested capital performance conditions.
The TSR condition measures the Groups TSR relative to a comparator group of other pharmaceutical companies.
The TSR vesting schedule dictates that 20% of awards vest for median performance and 100% for upper quartile performance, with pro-rata vesting in between these points.
No awards vest for performance which is below the median.
The threshold and maximum performance requirements for the revenue growth, earnings per share and return on invested capital performance conditions are detailed in page 104 to 105 of the remuneration report and a measured against the audited financial statements for the closest three year financial period to the grant and vesting dates.
172 173 173 HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2015 Financial Statements Continued Notes to the Consolidated Financial Statements Continued 38.
The estimated fair value of each share option granted in the LTIP was calculated by applying the Monte Carlo simulation methodology.
For awards made from 2011, 50% of the award is subject to a TSR performance condition which was valued by applying the Monte Carlo simulation methodology, the remaining 50% of the award is subject to financial metrics which are valued by applying the Black-Scholes model.
For further details see the remuneration committee report.
The exercise price of the share award is $nil.
Further details on the number of shares granted are as follows: 2014 2014 2014 2014 2013 2013 2012 2007 grants grants grants grants grants grants grant grants 03 Dec 14 June 29 May 3 Apr 6 Nov 17 May 16 March 23 April Total Year 2015 Number Number Number Number Number Number Number Number Number Outstanding at 1 January 5,899 151,429 109,000 84,954 20,802 431,876 468,250 13,000 1,285,210 Granted during the year Exercised during the year 440,430 440,430 Expired during the year forfeitures Expired during the year performance condition Outstanding at 31 December 5,899 151,429 109,000 84,954 20,802 431,876 27,820 13,000 844,780 Exercisable at 31 December 27,820 13,000 40,820 174 174 FINANCIAL STATEMENTS Notes to the Consolidated Financial Statements Continued 38.
10-Sep-2007 150,000 4.70 8.28 34.64% 0.08% 5.00% 23-Apr-2007 466,000 4.47 7.69 34.64% 0.08% 5.45% Management incentive plan 2-Apr-2007 160,000 4.33 7.46 34.64% 0.08% 5.40% The 2009 Management Incentive Plan MIP was approved by shareholders at the 2010 Annual General Meeting, whereby shareholders consented to the Company satisfying awards under the MIP from newly issued shares.
Under the MIP, the Company makes grants of All long-term incentive plans have ten years contractual life and vest after three years.
conditional awards to management across the Group below senior management level.
Awards are dependent on the achievement of The estimated fair value of each share option granted in the LTIP was calculated by applying the Monte Carlo simulation methodology.
individual and Group KPIs over one year and are then subject to a two year holding period.
The 2009 MIP awards were made at the start of For awards made from 2011, 50% of the award is subject to a TSR performance condition which was valued by applying the Monte Carlo the KPI performance period, whereas the 2011 awards and future awards will be made at the end of the KPI performance period.
simulation methodology, the remaining 50% of the award is subject to financial metrics which are valued by applying the Black-Scholes Details of the grants under the plan are shown below: model.
2015 grants 2014 grants 2013 grants The exercise price of the share award is $nil.
14-May 11-Jun 17 May Total Year 2015 Number Number Number Number Further details on the number of shares granted are as follows: Outstanding at 1 January 219,296 229,081 448,377 2014 2014 2014 2014 2013 2013 2012 2007 Granted during the year 145,918 145,918 grants grants grants grants grants grants grant grants 03 Dec 14 June 29 May 3 Apr 6 Nov 17 May 16 March 23 April Total Exercised during the year 725 211,554 212,279 Year 2015 Number Number Number Number Number Number Number Number Number Expired during the year 5,324 4,562 7,554 17,440 Outstanding at 1 January 5,899 151,429 109,000 84,954 20,802 431,876 468,250 13,000 1,285,210 Outstanding at 31 December 140,594 214,009 9,973 364,576 Granted during the year Exercised during the year 440,430 440,430 Expired during the year forfeitures Expired during the year performance condition Outstanding at 31 December 5,899 151,429 109,000 84,954 20,802 431,876 27,820 13,000 844,780 Exercisable at 31 December 27,820 13,000 40,820 174 175 175
